Hana Biosciences, Inc. Initiates Talotrexin Phase II Clinical Trials In Relapsed Or Refractory Non-Small Cell Lung Cancer (NSCLC)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--March 31, 2006--Completed Phase I Results to Be Presented at American Society of Clinical Oncology (ASCO) Meeting to Be Held June 2-6, 2006 in Atlanta. Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on advancing cancer care, announced that the company initiated a multicenter, multinational Phase II clinical trial with Talotrexin (PT-523) in relapsed or refractory non-small cell lung cancer (NSCLC).

Back to news